Loading…
Potential for brain accessibility and analysis of stability of selected flavonoids in relation to neuroprotection in vitro
Abstract Natural food sources constitute a promising source of new compounds with neuroprotective properties, once they have the ability to reach the brain. Our aim was to evaluate the brain accessibility of quercetin, epigallocatechin gallate (EGCG) and cyanidin-3-glucoside (C3G) in relation to the...
Saved in:
Published in: | Brain research 2016-11, Vol.1651, p.17-26 |
---|---|
Main Authors: | , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c456t-61693047c5f4aff0ce49062ceab377a11f13e4bf64c88e2b294d0bf598ce74323 |
---|---|
cites | cdi_FETCH-LOGICAL-c456t-61693047c5f4aff0ce49062ceab377a11f13e4bf64c88e2b294d0bf598ce74323 |
container_end_page | 26 |
container_issue | |
container_start_page | 17 |
container_title | Brain research |
container_volume | 1651 |
creator | Pogačnik, Lea Pirc, Katja Palmela, Inês Skrt, Mihaela Kwang, Kim S Brites, Dora Brito, Maria Alexandra Ulrih, Nataša Poklar Silva, Rui F.M |
description | Abstract Natural food sources constitute a promising source of new compounds with neuroprotective properties, once they have the ability to reach the brain. Our aim was to evaluate the brain accessibility of quercetin, epigallocatechin gallate (EGCG) and cyanidin-3-glucoside (C3G) in relation to their neuroprotective capability. Primary cortical neuron cultures were exposed to oxidative insult in the absence and presence of the selected compounds, and neuroprotection was assessed through evaluation of apoptotic-like and necrotic-like cell death. The brain accessibility of selected compounds was assessed using an optimised human blood-brain barrier model. The blood-brain barrier model was crossed rapidly by EGCG and more slowly by C3G, but not by quercetin. EGCG protected against oxidation-induced neuronal necrotic-like cell death by ~40%, and apoptosis by ~30%. Both quercetin and C3G were less effective, since only the lowest quercetin concentration was protective, and C3G only prevented necrosis by ~37%. Quercetin, EGCG and C3G effectively inhibited α-synuclein fibrillation over the relevant timescale applied here. Overall, EGCG seems to be the most promising neuroprotective compound. Thus, inclusion of this polyphenol in the diet might provide an affordable means to reduce the impact of neurodegenerative diseases. |
doi_str_mv | 10.1016/j.brainres.2016.09.020 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1837295520</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0006899316306485</els_id><sourcerecordid>1837295520</sourcerecordid><originalsourceid>FETCH-LOGICAL-c456t-61693047c5f4aff0ce49062ceab377a11f13e4bf64c88e2b294d0bf598ce74323</originalsourceid><addsrcrecordid>eNqFUU2PFCEQJUbjjqt_YcPRy7QFdNPNxWg260eyiSbqmdB0kTAyzQr0JOOvl56Z9eDFAyFFvXqPeo-QGwYNAybf7JoxGT8nzA2vdQOqAQ5PyIYNPd9K3sJTsgEAuR2UElfkRc67Wgqh4Dm54r0UamCwIb-_xoJz8SZQFxM9kVJjLebsRx98OVIzT_WYcMw-0-hoLubSWQsMaAtO1AVziHP0U6aVIWEwxceZlkhnXFJ8SFXHnp5q--BLii_JM2dCxleX-5r8-HD3_fbT9v7Lx8-37--3tu1k2UomlYC2t51rjXNgsVUguUUzir43jDkmsB2dbO0wIB-5aicYXacGi30ruLgmr8-89Q-_FsxF7322GIKZMS5Zs0H0XHUdhwqVZ6hNMeeETj8kvzfpqBno1Xe904--69V3DUrDafDmorGMe5z-jj0aXQHvzgCsmx48Jp2tx9ni5FP1RU_R_1_j7T8UNvjZWxN-4hHzLi6pplT30Zlr0N_W9NfwmRQg26ETfwAlyq9C</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1837295520</pqid></control><display><type>article</type><title>Potential for brain accessibility and analysis of stability of selected flavonoids in relation to neuroprotection in vitro</title><source>Elsevier</source><creator>Pogačnik, Lea ; Pirc, Katja ; Palmela, Inês ; Skrt, Mihaela ; Kwang, Kim S ; Brites, Dora ; Brito, Maria Alexandra ; Ulrih, Nataša Poklar ; Silva, Rui F.M</creator><creatorcontrib>Pogačnik, Lea ; Pirc, Katja ; Palmela, Inês ; Skrt, Mihaela ; Kwang, Kim S ; Brites, Dora ; Brito, Maria Alexandra ; Ulrih, Nataša Poklar ; Silva, Rui F.M</creatorcontrib><description>Abstract Natural food sources constitute a promising source of new compounds with neuroprotective properties, once they have the ability to reach the brain. Our aim was to evaluate the brain accessibility of quercetin, epigallocatechin gallate (EGCG) and cyanidin-3-glucoside (C3G) in relation to their neuroprotective capability. Primary cortical neuron cultures were exposed to oxidative insult in the absence and presence of the selected compounds, and neuroprotection was assessed through evaluation of apoptotic-like and necrotic-like cell death. The brain accessibility of selected compounds was assessed using an optimised human blood-brain barrier model. The blood-brain barrier model was crossed rapidly by EGCG and more slowly by C3G, but not by quercetin. EGCG protected against oxidation-induced neuronal necrotic-like cell death by ~40%, and apoptosis by ~30%. Both quercetin and C3G were less effective, since only the lowest quercetin concentration was protective, and C3G only prevented necrosis by ~37%. Quercetin, EGCG and C3G effectively inhibited α-synuclein fibrillation over the relevant timescale applied here. Overall, EGCG seems to be the most promising neuroprotective compound. Thus, inclusion of this polyphenol in the diet might provide an affordable means to reduce the impact of neurodegenerative diseases.</description><identifier>ISSN: 0006-8993</identifier><identifier>EISSN: 1872-6240</identifier><identifier>DOI: 10.1016/j.brainres.2016.09.020</identifier><identifier>PMID: 27639810</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>alpha-Synuclein - metabolism ; Animals ; Anthocyanins - pharmacokinetics ; Anthocyanins - pharmacology ; Antioxidants - pharmacokinetics ; Antioxidants - pharmacology ; Apoptosis ; Apoptosis - drug effects ; Apoptosis - physiology ; Blood–brain barrier ; Brain - drug effects ; Brain - metabolism ; Catechin - analogs & derivatives ; Catechin - pharmacokinetics ; Catechin - pharmacology ; Cells, Cultured ; Dose-Response Relationship, Drug ; Drug Evaluation, Preclinical ; Drug Stability ; Endothelial Cells - drug effects ; Endothelial Cells - metabolism ; Flavonoids ; Flavonoids - pharmacokinetics ; Flavonoids - pharmacology ; Glucosides - pharmacokinetics ; Glucosides - pharmacology ; Humans ; Necrosis ; Necrosis - drug therapy ; Necrosis - metabolism ; Neurology ; Neurons - drug effects ; Neurons - metabolism ; Neuroprotection ; Neuroprotective Agents - pharmacokinetics ; Neuroprotective Agents - pharmacology ; Oxidative Stress - drug effects ; Oxidative Stress - physiology ; Protein Multimerization - drug effects ; Quercetin - pharmacokinetics ; Quercetin - pharmacology ; Rats, Wistar ; Recombinant Proteins - metabolism ; α-synuclein fibrillation</subject><ispartof>Brain research, 2016-11, Vol.1651, p.17-26</ispartof><rights>2016 Elsevier B.V.</rights><rights>Copyright © 2016 Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c456t-61693047c5f4aff0ce49062ceab377a11f13e4bf64c88e2b294d0bf598ce74323</citedby><cites>FETCH-LOGICAL-c456t-61693047c5f4aff0ce49062ceab377a11f13e4bf64c88e2b294d0bf598ce74323</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27639810$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Pogačnik, Lea</creatorcontrib><creatorcontrib>Pirc, Katja</creatorcontrib><creatorcontrib>Palmela, Inês</creatorcontrib><creatorcontrib>Skrt, Mihaela</creatorcontrib><creatorcontrib>Kwang, Kim S</creatorcontrib><creatorcontrib>Brites, Dora</creatorcontrib><creatorcontrib>Brito, Maria Alexandra</creatorcontrib><creatorcontrib>Ulrih, Nataša Poklar</creatorcontrib><creatorcontrib>Silva, Rui F.M</creatorcontrib><title>Potential for brain accessibility and analysis of stability of selected flavonoids in relation to neuroprotection in vitro</title><title>Brain research</title><addtitle>Brain Res</addtitle><description>Abstract Natural food sources constitute a promising source of new compounds with neuroprotective properties, once they have the ability to reach the brain. Our aim was to evaluate the brain accessibility of quercetin, epigallocatechin gallate (EGCG) and cyanidin-3-glucoside (C3G) in relation to their neuroprotective capability. Primary cortical neuron cultures were exposed to oxidative insult in the absence and presence of the selected compounds, and neuroprotection was assessed through evaluation of apoptotic-like and necrotic-like cell death. The brain accessibility of selected compounds was assessed using an optimised human blood-brain barrier model. The blood-brain barrier model was crossed rapidly by EGCG and more slowly by C3G, but not by quercetin. EGCG protected against oxidation-induced neuronal necrotic-like cell death by ~40%, and apoptosis by ~30%. Both quercetin and C3G were less effective, since only the lowest quercetin concentration was protective, and C3G only prevented necrosis by ~37%. Quercetin, EGCG and C3G effectively inhibited α-synuclein fibrillation over the relevant timescale applied here. Overall, EGCG seems to be the most promising neuroprotective compound. Thus, inclusion of this polyphenol in the diet might provide an affordable means to reduce the impact of neurodegenerative diseases.</description><subject>alpha-Synuclein - metabolism</subject><subject>Animals</subject><subject>Anthocyanins - pharmacokinetics</subject><subject>Anthocyanins - pharmacology</subject><subject>Antioxidants - pharmacokinetics</subject><subject>Antioxidants - pharmacology</subject><subject>Apoptosis</subject><subject>Apoptosis - drug effects</subject><subject>Apoptosis - physiology</subject><subject>Blood–brain barrier</subject><subject>Brain - drug effects</subject><subject>Brain - metabolism</subject><subject>Catechin - analogs & derivatives</subject><subject>Catechin - pharmacokinetics</subject><subject>Catechin - pharmacology</subject><subject>Cells, Cultured</subject><subject>Dose-Response Relationship, Drug</subject><subject>Drug Evaluation, Preclinical</subject><subject>Drug Stability</subject><subject>Endothelial Cells - drug effects</subject><subject>Endothelial Cells - metabolism</subject><subject>Flavonoids</subject><subject>Flavonoids - pharmacokinetics</subject><subject>Flavonoids - pharmacology</subject><subject>Glucosides - pharmacokinetics</subject><subject>Glucosides - pharmacology</subject><subject>Humans</subject><subject>Necrosis</subject><subject>Necrosis - drug therapy</subject><subject>Necrosis - metabolism</subject><subject>Neurology</subject><subject>Neurons - drug effects</subject><subject>Neurons - metabolism</subject><subject>Neuroprotection</subject><subject>Neuroprotective Agents - pharmacokinetics</subject><subject>Neuroprotective Agents - pharmacology</subject><subject>Oxidative Stress - drug effects</subject><subject>Oxidative Stress - physiology</subject><subject>Protein Multimerization - drug effects</subject><subject>Quercetin - pharmacokinetics</subject><subject>Quercetin - pharmacology</subject><subject>Rats, Wistar</subject><subject>Recombinant Proteins - metabolism</subject><subject>α-synuclein fibrillation</subject><issn>0006-8993</issn><issn>1872-6240</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><recordid>eNqFUU2PFCEQJUbjjqt_YcPRy7QFdNPNxWg260eyiSbqmdB0kTAyzQr0JOOvl56Z9eDFAyFFvXqPeo-QGwYNAybf7JoxGT8nzA2vdQOqAQ5PyIYNPd9K3sJTsgEAuR2UElfkRc67Wgqh4Dm54r0UamCwIb-_xoJz8SZQFxM9kVJjLebsRx98OVIzT_WYcMw-0-hoLubSWQsMaAtO1AVziHP0U6aVIWEwxceZlkhnXFJ8SFXHnp5q--BLii_JM2dCxleX-5r8-HD3_fbT9v7Lx8-37--3tu1k2UomlYC2t51rjXNgsVUguUUzir43jDkmsB2dbO0wIB-5aicYXacGi30ruLgmr8-89Q-_FsxF7322GIKZMS5Zs0H0XHUdhwqVZ6hNMeeETj8kvzfpqBno1Xe904--69V3DUrDafDmorGMe5z-jj0aXQHvzgCsmx48Jp2tx9ni5FP1RU_R_1_j7T8UNvjZWxN-4hHzLi6pplT30Zlr0N_W9NfwmRQg26ETfwAlyq9C</recordid><startdate>20161115</startdate><enddate>20161115</enddate><creator>Pogačnik, Lea</creator><creator>Pirc, Katja</creator><creator>Palmela, Inês</creator><creator>Skrt, Mihaela</creator><creator>Kwang, Kim S</creator><creator>Brites, Dora</creator><creator>Brito, Maria Alexandra</creator><creator>Ulrih, Nataša Poklar</creator><creator>Silva, Rui F.M</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope></search><sort><creationdate>20161115</creationdate><title>Potential for brain accessibility and analysis of stability of selected flavonoids in relation to neuroprotection in vitro</title><author>Pogačnik, Lea ; Pirc, Katja ; Palmela, Inês ; Skrt, Mihaela ; Kwang, Kim S ; Brites, Dora ; Brito, Maria Alexandra ; Ulrih, Nataša Poklar ; Silva, Rui F.M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c456t-61693047c5f4aff0ce49062ceab377a11f13e4bf64c88e2b294d0bf598ce74323</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>alpha-Synuclein - metabolism</topic><topic>Animals</topic><topic>Anthocyanins - pharmacokinetics</topic><topic>Anthocyanins - pharmacology</topic><topic>Antioxidants - pharmacokinetics</topic><topic>Antioxidants - pharmacology</topic><topic>Apoptosis</topic><topic>Apoptosis - drug effects</topic><topic>Apoptosis - physiology</topic><topic>Blood–brain barrier</topic><topic>Brain - drug effects</topic><topic>Brain - metabolism</topic><topic>Catechin - analogs & derivatives</topic><topic>Catechin - pharmacokinetics</topic><topic>Catechin - pharmacology</topic><topic>Cells, Cultured</topic><topic>Dose-Response Relationship, Drug</topic><topic>Drug Evaluation, Preclinical</topic><topic>Drug Stability</topic><topic>Endothelial Cells - drug effects</topic><topic>Endothelial Cells - metabolism</topic><topic>Flavonoids</topic><topic>Flavonoids - pharmacokinetics</topic><topic>Flavonoids - pharmacology</topic><topic>Glucosides - pharmacokinetics</topic><topic>Glucosides - pharmacology</topic><topic>Humans</topic><topic>Necrosis</topic><topic>Necrosis - drug therapy</topic><topic>Necrosis - metabolism</topic><topic>Neurology</topic><topic>Neurons - drug effects</topic><topic>Neurons - metabolism</topic><topic>Neuroprotection</topic><topic>Neuroprotective Agents - pharmacokinetics</topic><topic>Neuroprotective Agents - pharmacology</topic><topic>Oxidative Stress - drug effects</topic><topic>Oxidative Stress - physiology</topic><topic>Protein Multimerization - drug effects</topic><topic>Quercetin - pharmacokinetics</topic><topic>Quercetin - pharmacology</topic><topic>Rats, Wistar</topic><topic>Recombinant Proteins - metabolism</topic><topic>α-synuclein fibrillation</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pogačnik, Lea</creatorcontrib><creatorcontrib>Pirc, Katja</creatorcontrib><creatorcontrib>Palmela, Inês</creatorcontrib><creatorcontrib>Skrt, Mihaela</creatorcontrib><creatorcontrib>Kwang, Kim S</creatorcontrib><creatorcontrib>Brites, Dora</creatorcontrib><creatorcontrib>Brito, Maria Alexandra</creatorcontrib><creatorcontrib>Ulrih, Nataša Poklar</creatorcontrib><creatorcontrib>Silva, Rui F.M</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><jtitle>Brain research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pogačnik, Lea</au><au>Pirc, Katja</au><au>Palmela, Inês</au><au>Skrt, Mihaela</au><au>Kwang, Kim S</au><au>Brites, Dora</au><au>Brito, Maria Alexandra</au><au>Ulrih, Nataša Poklar</au><au>Silva, Rui F.M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Potential for brain accessibility and analysis of stability of selected flavonoids in relation to neuroprotection in vitro</atitle><jtitle>Brain research</jtitle><addtitle>Brain Res</addtitle><date>2016-11-15</date><risdate>2016</risdate><volume>1651</volume><spage>17</spage><epage>26</epage><pages>17-26</pages><issn>0006-8993</issn><eissn>1872-6240</eissn><abstract>Abstract Natural food sources constitute a promising source of new compounds with neuroprotective properties, once they have the ability to reach the brain. Our aim was to evaluate the brain accessibility of quercetin, epigallocatechin gallate (EGCG) and cyanidin-3-glucoside (C3G) in relation to their neuroprotective capability. Primary cortical neuron cultures were exposed to oxidative insult in the absence and presence of the selected compounds, and neuroprotection was assessed through evaluation of apoptotic-like and necrotic-like cell death. The brain accessibility of selected compounds was assessed using an optimised human blood-brain barrier model. The blood-brain barrier model was crossed rapidly by EGCG and more slowly by C3G, but not by quercetin. EGCG protected against oxidation-induced neuronal necrotic-like cell death by ~40%, and apoptosis by ~30%. Both quercetin and C3G were less effective, since only the lowest quercetin concentration was protective, and C3G only prevented necrosis by ~37%. Quercetin, EGCG and C3G effectively inhibited α-synuclein fibrillation over the relevant timescale applied here. Overall, EGCG seems to be the most promising neuroprotective compound. Thus, inclusion of this polyphenol in the diet might provide an affordable means to reduce the impact of neurodegenerative diseases.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>27639810</pmid><doi>10.1016/j.brainres.2016.09.020</doi><tpages>10</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0006-8993 |
ispartof | Brain research, 2016-11, Vol.1651, p.17-26 |
issn | 0006-8993 1872-6240 |
language | eng |
recordid | cdi_proquest_miscellaneous_1837295520 |
source | Elsevier |
subjects | alpha-Synuclein - metabolism Animals Anthocyanins - pharmacokinetics Anthocyanins - pharmacology Antioxidants - pharmacokinetics Antioxidants - pharmacology Apoptosis Apoptosis - drug effects Apoptosis - physiology Blood–brain barrier Brain - drug effects Brain - metabolism Catechin - analogs & derivatives Catechin - pharmacokinetics Catechin - pharmacology Cells, Cultured Dose-Response Relationship, Drug Drug Evaluation, Preclinical Drug Stability Endothelial Cells - drug effects Endothelial Cells - metabolism Flavonoids Flavonoids - pharmacokinetics Flavonoids - pharmacology Glucosides - pharmacokinetics Glucosides - pharmacology Humans Necrosis Necrosis - drug therapy Necrosis - metabolism Neurology Neurons - drug effects Neurons - metabolism Neuroprotection Neuroprotective Agents - pharmacokinetics Neuroprotective Agents - pharmacology Oxidative Stress - drug effects Oxidative Stress - physiology Protein Multimerization - drug effects Quercetin - pharmacokinetics Quercetin - pharmacology Rats, Wistar Recombinant Proteins - metabolism α-synuclein fibrillation |
title | Potential for brain accessibility and analysis of stability of selected flavonoids in relation to neuroprotection in vitro |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T18%3A43%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Potential%20for%20brain%20accessibility%20and%20analysis%20of%20stability%20of%20selected%20flavonoids%20in%20relation%20to%20neuroprotection%20in%20vitro&rft.jtitle=Brain%20research&rft.au=Poga%C4%8Dnik,%20Lea&rft.date=2016-11-15&rft.volume=1651&rft.spage=17&rft.epage=26&rft.pages=17-26&rft.issn=0006-8993&rft.eissn=1872-6240&rft_id=info:doi/10.1016/j.brainres.2016.09.020&rft_dat=%3Cproquest_cross%3E1837295520%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c456t-61693047c5f4aff0ce49062ceab377a11f13e4bf64c88e2b294d0bf598ce74323%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1837295520&rft_id=info:pmid/27639810&rfr_iscdi=true |